Chromocell Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Chromocell Therapeutics generated cash of -$981,031, which is more than the previous year. Cash used in financing activities reached the amount of $1,022,348 last year. Net change in cash is therefore $41,317.
Cash Flow
| 2022 | -1.56M | 0 | 1.62M |
|---|---|---|---|
| 2023 | -981.03K | 0 | 1.02M |
CHRO Cash Flow Statement (2022 – 2023)
| 2023 | 2022 | |
|---|---|---|
Cash at beginning of period | 55.07K | 0 |
Operating activities | ||
Net income | -7.38M | -2.45M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||
Depreciation and amortization | 188.11K | 0 |
Stock-based compensation expense | 3.95M | 110.14K |
| Deferred income tax benefit | 3.95M | 110.14K |
| Changes in operating assets and liabilities: | ||
Accounts receivable, net | 0 | 0 |
Inventories | 0 | 0 |
Accounts payable | 1.62M | 413.60K |
Cash generated by operating activities | -981.03K | -1.56M |
Investing activities | ||
Purchases Of Investments | 0 | 0 |
Investments In Property Plant And Equipment | 1 | 0 |
Acquisitions Net | 0 | 0 |
Cash generated by investing activities | 0 | 0 |
Financing activities | ||
Common Stock Issued | 255.41K | 0 |
Payments for dividends | 0 | 0 |
Repurchases of common stock | 0 | 0 |
Repayments of term debt | 766.93K | 400K |
Cash used in financing activities | 1.02M | 1.62M |
Net Change In Cash | 41.31K | 55.07K |
Cash at end of period | 96.39K | 55.07K |
| Data source |